Managements job is to also get the story across to analysts & institutional investors in addition to delivering on the science.
Just keep telling yourselves that everything is great. Every failure & delay just increases the chances for a cash raise.
Pjmyers, the reason I said no was because the therapeutic equivalent is not the issue. Mylan is not arguing about the drug but the device as you note. Have you read the Citizen Petition?
stock will trade on a positive decision. On one hand the low float & high short interest would make you think that $18 or $19 is possible. On the other hand I'm not sure how much buying will occur at higher prices or short covering since no one can really get a handle on how well the launch will go. If that's the case then maybe the stock will settle in the $14 or $15 range.
ACAD,AERI,PTLA. I also like the ONCS, IPO this week.
I definitely think you need to look for stocks with upcoming binary events or they are in Phase III. There is so many opportunities that investors are moving out of the weaker or earlier stage plays.
Most of my plays were recommended by Andre,
Maybe ATRS is waiting to hire new sales reps before they get the judges decision.
" Nov. 24, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company, today announced that it has filed a motion for a preliminary injunction against Antares Pharma, Inc. to prohibit sales of the 15, 20 and 25 mg doses of Otrexup™ (methotrexate) injection to new patients. The motion was filed in the United States District Court for the District of New Jersey in a suit for infringement of the U.S. patent 8,664,231 (the '231 patent). The patent, titled, "Concentrated Methotrexate Solutions," is directed to a method for the treatment of inflammatory autoimmune diseases by subcutaneously administrating methotrexate at a concentration of more than 30 mg/mL. Medac Pharma's Rasuvo™ (methotrexate injection) is available to fill the treatment needs of any patient affected by the requested injunction."
I don't want to argue about it. You've believed the talking points from Howarth or whoever you talk to at ATRS & been nice enough to post that on the board. I've been the jerk who argued against those talking points but I've also been proven more accurate then them.
The superior technology that ATRS used would limit Medac's ability to gain market share with Rasuvo. That Rasuvo was not a threat & would actually open up the market.
I agree that a few weeks prior to Medac's approval you knew there was no stopping them but this was not known until some poster appeared on the board & revealed the backdoor process. Prior to that point, you believed & Howarth told investors that Medac didn't have a snow balls chance.
Hernia surgery, your supposed to take it easy for 6 - 8 weeks so no golf for me. I have no idea how people get addicted to percocet's. Screwed my stomach up so bad I never want to take another one.
That's pretty funny. One problem is that its sunny & 50 degrees in New Orleans. Problem is I had surgery a week ago & I've got nothing better to do then sit on the computer.
Everyone wants to say that its no big deal that one works slightly different then the other. I just think that's a huge mistake. The Citizens Petition clearly references emergency use drugs which have a higher standard.
One more thought. If TEVA/ATRS's injector gets approved then they could market it as an improved version of the branded drug. This creates confusion in the marketplace & that's not what an AB rated product is intended to do. It should function the same as the originator.
The FDA might not agree with these thoughts but I can see where Mylan is coming from.